1-3 of 3
David Ramies
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

New Acalabrutinib Formulation Enables Co-Administration with Proton Pump Inhibitors and Dosing in Patients Unable to Swallow Capsules (ELEVATE-PLUS)

Shringi Sharma, Xavier Pepin, Harini Burri, Lianqing Zheng, Nataliya Kuptsova-Clarkson, Anouk de Jong, Ting Yu, Holly L MacArthur, Michal Majewski, Joseph A Ware, James Mann, David Ramies, Veerendra Munugalavadla, Louise Sheridan, Helen Tomkinson
Journal: Blood
Blood (2021) 138 (Supplement 1): 4365.
https://doi.org/10.1182/blood-2021-146610
Published: 2021
Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4767.
https://doi.org/10.1182/blood-2019-123688
Published: 2019
Journal Articles

Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic Syndrome (MDS)

Michael K Keng, MD, Samer K. Khaled, MD, Brenda Cooper, MD, Erica D. Warlick, MD, David Ramies, MD, Silvia Mappa, MD, Ehab L. Atallah, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4362.
https://doi.org/10.1182/blood-2018-99-112741
Published: 2018